FDA EUA Issued for LumiraDx Covid-19 Antigen Test
FDA has authorized the covid-19 antigen test for use in high and moderate complexity laboratories certified under CLIA and at the point of care.
Read MoreSearch Results for: point-of-care
miR Scientific Noninvasive Prostate Cancer Test Validation Published
miR Scientific’s urine-based, noninvasive cancer test can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%.
Read More
Blood Test May Point to Higher Risk for Covid-19 Death
Elevated levels of these five biomarkers were associated with inflammation and bleeding disorder as well as increased risk of death in covid-19 patients.
Read More
Sight Diagnostics Expanding Fingerstick CBC Testing
The Israeli company behind the first FDA-cleared direct-from-fingerstick CBC analyzer plans to expand its operations in the United States.
Read More
Fujirebio Begins Testing for Fully Automated SARS-CoV-2 Antigen Assay
Fujirebio Diagnostics has begun the clinical testing of its new SARS-CoV-2 antigen assay with the goal of providing the first fully automated antigen test.
Read More